Aprea Therapeutics Inc. (APRE)
NASDAQ: APRE
· Real-Time Price · USD
1.72
0.03 (1.78%)
At close: Aug 15, 2025, 2:22 PM
1.78% (1D)
| Bid | 1.69 |
| Market Cap | 9.99M |
| Revenue (ttm) | 767.39K |
| Net Income (ttm) | -14.08M |
| EPS (ttm) | -2.3 |
| PE Ratio (ttm) | -0.75 |
| Forward PE | -1.16 |
| Analyst | Buy |
| Ask | 1.74 |
| Volume | 11,259 |
| Avg. Volume (20D) | 51,496 |
| Open | 1.71 |
| Previous Close | 1.69 |
| Day's Range | 1.69 - 1.75 |
| 52-Week Range | 1.41 - 5.01 |
| Beta | 1.30 |
About APRE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol APRE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for APRE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+17.65%
Aprea Therapeutics shares are trading higher on co...
Unlock content with
Pro Subscription
5 months ago
+9.87%
Aprea Therapeutics shares are trading higher after the company announced it entered a medical transfer agreement with MD Anderson Cancer Center to explore APR-105 as a potential treatment for head and neck squamous cell carcinoma.
